Table 1. Identified PFKFB3 inhibitors that induce cell proliferation suppression in tumor cells.

Tumor types	Characteristics of tumor cells	PFKFB3 inhibitors	Synergetic agents	References
Acute myeloid leukemia	mTOR hyper-activated	PFK15	rapamycin	[6]
Acute lymphoblastic leukemia		3PO, PFK15		[40]
Head and neck squamous cell carcinoma		PFK15		[34]
Colon adenocarcinoma		PFK15		[40]
Pancreatic adenocarcinoma		PFK15		[40]
Glioblastoma		PFK15		[40]
Lung carcinoma		PFK15		[40]
Gastric cancer		PFK15		[41]
Breast cancer	ER+	PFK158	estradiol	[42]
Breast cancer	HER2+, resistance to trastuzumab	3PO	HER2 antagonist (lapatinib)	[44]
Melanoma	BRAFV600E mutant	PFK158	Vemurafenib	[43]

Abbreviations: mTOR : mechanistic target of rapamycin, HER2: human epidermal growth factor receptor-2, ER: estrogen receptor.